Risk of rash and stomatitis with temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis.
C. Gomez Fernandez
No relevant relationships to disclose
Y. Balagula
No relevant relationships to disclose
S. Wu
Honoraria - Novartis; Onyx; Wyeth
X. Su
No relevant relationships to disclose
D. R. Feldman
Consultant or Advisory Role - Pfizer
D. E. Rathkopf
No relevant relationships to disclose
M. E. Lacouture
Consultant or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Genzyme; GlaxoSmithKline; Hana BioSciences; ImClone Systems; Lilly; Onyx; OSI Pharmaceuticals; Pfizer; Roche; Wyeth
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Genzyme; GlaxoSmithKline; Hana BioSciences; ImClone Systems; Lilly; Onyx; OSI Pharmaceuticals; Pfizer; Roche; Wyeth
Research Funding - Hana BioSciences; Onyx